MPE05-Translational Research in Cardiovascular Diseases
Precision Medicine / IBS-MPE05 / Consolidated
A group of professionals, mostly from the field of cardiology, who base their research work on the study of cardiac pathologies, their etiology, development and updating of treatment alternatives.
Research lines
- Cachexia and nutrition in patients with HF and LV systolic dysfunction
- Nursing health education for patients with HF (secondary prevention).
- Effect of hisian pacing on pacing-induced cardiomyopathy.
- Effect of physical exercise on arrhythmic risk in patients with arrhythmogenic cardiomyopathy.
- Cardiovascular pharmacogenetics
- Iron deficiency in patients with HF and LV systolic dysfunction.
- Genetics of sudden cardiac death and inherited heart diseases.
- Multidisciplinary management of CI.
- Pulmonary hypertension after mitral valve surgery.
- Impact of psychological factors in Acute Coronary Syndromes: Incidence, pathophysiological mechanisms and intervention procedures.
- Influence of the Mediterranean diet in recurrences of atrial fibrillation.
- Sudden cardiac death in adult patients with congenital heart disease.
- Navigation without scope for ablation of cardiac arrhythmias.
- Clinical and echocardiographic parameters that determine the indication and type of repair in tricuspid regurgitation.
- Mortality patterns and readmissions in patients with HF.
- PRISMA Project: Spanish reference center for training in CI Units
EVA CABRERA BORREGO
DIEGO GINES SEGURA RODRIGUEZ
RICARDO FRANCISCO RIVERA LOPEZ
FRANCISCO JOSE BERMUDEZ JIMENEZ
MARIA BELEN GARCIA ORTEGA
JOAQUIN SANCHEZ GILA
PABLO SANCHEZ MILLAN
LUIS THIRD SANCHEZ
EDUARDO MOLINA NAVARRO
MANUEL MOLINA LERMA
EDUARDO MORENO ESCOBAR
JOSE ANTONIO RAMIREZ HERNANDEZ
JESUS GABRIEL SANCHEZ RAMOS
JUAN KNIGHT BORREGO
ROCIO GARCIA ORTA
JUAN JIMENEZ JAIMEZ
MIRIAM JIMENEZ FERNANDEZ
MANUEL LOPEZ PEREZ
SILVIA LOPEZ FERNANDEZ
ROSE MACIAS RUIZ
MIGUEL ALVAREZ LOPEZ
ANTONIO LUIS ARREBOLA MORENO
Extracellular Kir2.1C122Y Mutant Upsets Kir2.1-PIP2 Bonds and Is Arrhythmogenic in Andersen-Tawil Syndrome
CIRCULATION RESEARCH, 2024;
FI: 16,5; D1
Giant intramyocardial mass: a rare cause of bifascicular block
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2024;
FI: 6,7; D1
Arrhythmic Risk in Biventricular Pacing Compared With Left Bundle Branch Area Pacing: Results From the I-CLAS Study
CIRCULATION, 2024;
FI: 35,6; D1
The Kir2.1E299V mutation increases atrial fibrillation vulnerability while protecting the ventricles against arrhythmias in a mouse model of short QT syndrome type 3
CARDIOVASCULAR RESEARCH, 2024;
FI: 10,4; D1
Unexpected Response of Parahisian Resetting During an Orthodromic Atrioventricular Re-Entrant Tachycardia
JACC-CLINICAL ELECTROPHYSIOLOGY, 2024;
FI: 8; D1
Valve repair in mitral endocarditis
CARDIOVASCULAR SURGERY, 2023;
Autothreshold algorithm feasibility and safety in left bundle branch pacing
EUROPACE, 2023;
FI: 6,1; Q1
Comparison of automated subcutaneous defibrillator screening between different pacing sites in cardiac pacing device carriers
EUROPACE, 2023;
FI: 6,1; Q1
ROD2 domain filamin C missense mutations exhibit a distinctive cardiac phenotype with restrictive/hypertrophic cardiomyopathy and saw-tooth myocardium
SPANISH JOURNAL OF CARDIOLOGY, 2023;
FI: 5,9; Q1
Lifestyle physical activity and rapid-rate non-sustained ventricular tachycardia in arrhythmogenic cardiomyopathy
HEART, 2023;
FI: 5,7; Q2
Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries
EUROPEAN HEART JOURNAL, 2022;
FI: 35,855; D1
Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022;
FI: 27,203; D1
Natural History of MYH7-Related Dilated Cardiomyopathy
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022;
FI: 27,203; D1
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022;
FI: 27,203; D1
Instantaneous Wave-Free Ratio for the Assessment of Intermediate Left Main Coronary Artery Stenosis: Correlations With Fractional Flow Reserve/Intravascular Ultrasound and Prognostic Implications: The iLITRO-EPIC07 Study
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2022;
FI: 7,514; Q1
Ablation with zero-fluoroscopy of premature ventricular complexes from aortic sinus cusps: A single-center experience
JOURNAL OF ARRHYTHMIA, 2021;
A new molecular classification to drive precision treatment strategies in primary Sjogren's syndrome
NATURE COMMUNICATIONS, 2021;
FI: 14,919; D1
Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021;
FI: 24,093; D1
Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure
JAMA CARDIOLOGY, 2021;
FI: 14,676; D1
Clinical outcome of COVID-19 in patients with adult congenital heart disease
HEART, 2021;
FI: 5,994; Q1
A Remote Nutritional Intervention to Change the Dietary Habits of Patients Undergoing Ablation of Atrial Fibrillation: Randomized Controlled Trial
JOURNAL OF MEDICAL INTERNET RESEARCH, 2020;
FI: 5,034; D1
Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry.
EUROPEAN JOURNAL OF HEART FAILURE, 2020;
FI: 11,627; D1
Absence of relevant QT interval prolongation in not critically ill COVID-19 patients
SCIENTIFIC REPORTS, 2020;
FI: 3,998; Q1
Atrioventricular block in patients undergoing treatment with bradycardiic drugs. Predictors of pacemaker requirement (vol 73, pg 554, 2020)
SPANISH JOURNAL OF CARDIOLOGY, 2020;
FI: 4,642; Q1
Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5
HEART RHYTHM, 2020;
FI: 5,731; Q1
Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry.
EUROPEAN HEART JOURNAL, 2019;
FI: 24,889; D1
Two Novel Cases of Autosomal Recessive Noonan Syndrome Associated With LZTR1 Variants
SPANISH JOURNAL OF CARDIOLOGY, 2019;
FI: 5,078; Q1
Digenic Heterozygosity in SCN5A and CACNA1C Explains the Variable Expressivity of the Long QT Phenotype in a Spanish Family
SPANISH JOURNAL OF CARDIOLOGY, 2019;
FI: 5,078; Q1
Social support buffers the negative effects of stress in cardiac patients: a cross-sectional study with acute coronary syndrome patients.
JOURNAL OF BEHAVIORAL MEDICINE, 2019;
FI: 2,868; Q1
Genotype, Family History, and Outcomes in Noncompaction Cardiomyopathy
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018;
FI: 16,834; D1
Giant biventricular aneurysms: a novel cardiac phenotype in myotubular / centronuclear myopathy
EUROPEAN HEART JOURNAL, 2018;
FI: 23,425; D1
Novel Desmin Mutation p.Glu401Asp Impairs Filament Formation, Disrupts Cell Membrane Integrity, and Causes Severe Arrhythmogenic Left Ventricular Cardiomyopathy / Dysplasia
CIRCULATION, 2018;
FI: 18,881; D1
Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018;
FI: 16,834; D1
Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial
EUROPEAN HEART JOURNAL, 2018;
FI: 23,425; D1
Exercise for Patients With Hypertrophic Cardiomyopathy
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017;
FI: 44,405; D1
Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry.
EUROPEAN JOURNAL OF HEART FAILURE, 2017;
FI: 6,968; D1
Nonfluoroscopic Catheter Ablation. Results From a Prospective Multicenter Registry
SPANISH JOURNAL OF CARDIOLOGY, 2017;
FI: 4,485; Q1
Letter to Editor: Functional study is not the only criterion to predict the pathogenicity of a novel mutation for cardiomyopathy.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2017;
FI: 5,68; Q1
Clinical and Genetic Diagnosis of Nonischemic Sudden Cardiac Death
SPANISH JOURNAL OF CARDIOLOGY, 2017;
FI: 4,485; Q1
Sudden Cardiac Death in Children and Young Adults
NEW ENGLAND JOURNAL OF MEDICINE, 2016;
FI: 59,558; D1
Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016;
FI: 17,759; D1
Clinical Profile of Arrhythmogenic Right Ventricular Cardiomyopathy With Left Ventricular Involvement
SPANISH JOURNAL OF CARDIOLOGY, 2016;
FI: 4,596; Q1
Calmodulin 2 Mutation N98S Is Associated with Unexplained Cardiac Arrest in Infants Due to Low Clinical Penetrance Electrical Disorders
PLOSONE, 2016;
FI: 3,057; Q1
Letter by Jimenez-Jaimez and Tercedor Sanchez Regarding Article, "Outcome of Apparently Unexplained Cardiac Arrest: Results From Investigation and Follow-Up of the Prospective Cardiac Arrest Survivors With Preserved Ejection Fraction Registry"
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2016;
FI: 4,428; Q1
A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents The RIBS IV Randomized Clinical Trial
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015;
FI: 16,503; D1
Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation? The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2015;
FI: 5,906; D1
Asymptomatic 43-year-old man with family history of sudden death
HEART, 2015;
FI: 5,595; Q1
Ablation of frequent PVC in patients meeting criteria for primary prevention ICD implant: Safety of withholding the implant
HEART RHYTHM, 2015;
FI: 5,076; Q1
A meta-analysis of published studies of endothelial dysfunction does not support its routine clinical use
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2015;
FI: 2,566; Q1
ODIN-2023 Leveraging AI based technology to transform the future of health care delivery in Leading Hospitals in Europe
Funder: EUROPEAN COMMISSION
File number: ODIN-2023
Execution time: 05/09/2023 - 31/08/2024
PI: EDUARDO MOLINA NAVARRO
Genotype Specific Arrhythmogenic Mechanisms in Andersen-Tawil Syndrome
Funder: FOUNDATION LA MARATO DE TV3
File number: LAMARATO-2020-01
Execution time: 15/12/2020 - 14/12/2023
IP: JUAN JIMENEZ JAIMEZ
PREDICTORS OF COMPLICATION OF THORACIC ANEURYSM IN GENETIC AND BICUSPID AORTOPATHY.
Funder: COUNCIL OF HEALTH AND FAMILIES
File number: PI-0201-2020
Execution time: 01/01/2021 - 31/12/2023
PI: ROCIO GARCIA ORTA
Randomized trial of prevention of recurrent arrhythmias with a Mediterranean diet (PREDIMAR study) in patients with atrial fibrillation.
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI17 / 01870
Execution time: 01/01/2018 - 31/12/2020
IP: LUIS TERCEDOR SANCHEZ
EVALUATION OF THE EFFECT OF PHYSICAL EXERCISE ON ARRHYTHM RISK IN PATIENTS WITH ARRHYTHMOGENIC MYOCARDIOPATHY: OBSERVATIONAL, PROSPECTIVE, MULTICENTRIC STUDY
Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)
File number: PI-0398-2018
Execution time: 01/01/2019 - 31/12/2021
IP: JUAN JIMENEZ JAIMEZ
EFFECT OF HISIAN STIMULATION ON STIMULATION-INDUCED MYOCARDIOPATHY: A COMPARATIVE STUDY WITH CONVENTIONAL BIVENTRICULAR RESYNCHRONIZATION
Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)
File number: PI-0365-2018
Execution time: 01/01/2019 - 31/12/2021
PI: MANUEL MOLINA LERMA
ATTRACKING Registration
Funder: Carlos III National Center for Cardiovascular Research
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 29/11/24 - 30/11/28
PI: ROSA MACIAS RUIZ
Left septal or deep septal stimulation to prevent pacing-induced cardiomyopathy: DEEP (Left septal or DEEP septal stimulation to prevent pacing-induced cardiomyopathy) randomized clinical trial.
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 28/06/24 - 30/12/26
PI: MANUEL MOLINA LERMA
Evaluation of the safety and efficacy of a new range of sheaths for implanting probes in the interventricular septum.
Funder: SORIN CRM SAS
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 09/08/24 - 31/05/25
PI: MANUEL MOLINA LERMA
Shock reduction using multiple bursts of antitachycardia pacing for rapid ventricular tachycardias in implantable cardioverter-defibrillator patients. Code PI21/00857. STIMULATED
Funder: INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL)
Type of test: CLINICAL RESEARCH WITH MEDICAL DEVICES
Execution time: 30/04/2024 - 30/12/2026
IP: PABLO SANCHEZ MILLAN
Defibrillator Lead Evaluation and Reliability Study for Left Bundle Branch Pacing. LEADR LBBAP
Funder: MEDTRONIC BAKKEN RESEARCH CENTER BV
Type of test: CLINICAL RESEARCH WITH MEDICAL DEVICES
Execution time: 24/04/2024 - 31/12/2027
PI: MANUEL MOLINA LERMA
PREVAIL Paclitaxel-coated balloon in small coronary disease and high-bleeding risk patients.
Funder: EPIC FOUNDATION
Type of test: CLINICAL RESEARCH WITH MEDICAL DEVICES
Execution time: 01/04/2024 - 28/02/2027
IP: JUAN CABALLERO BORREGO
Prevalence in Spain of poor anticoagulation control in patients with 'non-valvular' atrial fibrillation treated with vitamin K antagonists.
Funder: CASA DEL CORAZON FOUNDATION
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 24/04/2023 - 30/12/2024
IP: Prevalence in Spain of poor anticoagulation control in patients with 'non-valvular' atrial fibrillation treated with vitamin K antagonists.
Post-marketing clinical surveillance plan (PMCF) to evaluate the safety and clinical effectiveness of the Supraflex Cruz TM coronary stent in the treatment of multivessel coronary artery disease
Funder: EPIC FOUNDATION
Type of test: CLINICAL RESEARCH WITH PROD. SANIT.
Execution time: 05/05/2023 - 30/07/2025
IP: JUAN CABALLERO BORREGO
Randomized, double-blind, placebo-controlled clinical trial to evaluate mavacamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathy
Financier: MYOKARDIA, INC.
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 24/03/2023 - 30/07/2025
IP: JUAN JIMENEZ JAIMEZ
A phase IV, double-blind, placebo-controlled, randomized withdrawal trial to evaluate the use of sodium zirconium cyclosilicate (CSZ) for the treatment of hyperkalemia in patients with symptomatic heart failure with a D fraction.
Funder: ASTRAZENECA AB
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 06/07/2023 - 30/12/2024
IP: DIEGO GINES SEGURA RODRIGUEZ
Treatment of functionally insignificant vulnerable plaques in patients with ST-elevation myocardial infarction and multivessel disease. (VULNERABLE Study).
Funder: EPIC FOUNDATION
Type of test: CLINICAL RESEARCH WITH PROD. SANIT.
Execution time: 10/04/2023 - 30/01/2029
IP: JUAN CABALLERO BORREGO
Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of abelacimab in high-risk patients with atrial fibrillation who are not considered suitable for
Funder: ANTHOS THERAPEUTICS
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 30/06/2023 - 28/05/2025
IP: LUIS TERCEDOR SANCHEZ
Cardiovascular and renal treatment in patients with heart failure with hyperkalemia or at high risk of hyperkalemia (CARE-HK in the HF registry)
Financier: VIFOR (INTERNATIONAL) INC.
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 08/02/2022 - 30/04/2025
IP: SILVIA LOPEZ FERNANDEZ
improveD procEdural workfLow for catheter ablation of paroxysmal AF with high density mapping system and advanced technology DELETE AF study.
Financier: UNIVERSITY OF NAVARRA CLINIC
Type of test: CLINICAL RESEARCH WITH PROD. SANIT.
Execution time: 07/10/2022 - 30/03/2025
IP: MIGUEL ALVAREZ LOPEZ
Early initiation of treatment with Candesartan vs Placebo in genetic carriers of causative DCM mutations without evidence of disease (EARLY-GENE trial)
Funder: FOUNDATION FOR BIOMEDICAL RESEARCH OF THE PUERTA DE HIERRO MAJADAHONDA UNIVERSITY HOSPITAL
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 30/03/2022 - 30/05/2026
IP: JUAN JIMENEZ JAIMEZ
A Global Prospective observationAl Study of Real-world management of patients With atrial fibrillation at High Risk of Stroke (GARDENIA)
Funder: ANTHOS THERAPEUTICS
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 20/12/2022 - 31/10/2024
PI: ROSA MACIAS RUIZ
A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Financier: MYOKARDIA, INC.
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 08/12/2022 - 01/08/2023
IP: JUAN JIMENEZ JAIMEZ
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of New-Onset Symptomatic Atrial Fibrillation to Sinus Rhythm (RESTORE-1)
Funder: INCARDA THERAPEUTICS, INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 28/11/2022 - 30/08/2023
IP: LUIS TERCEDOR SANCHEZ
Phase 3, multicenter, randomized, double-blind, placebo-controlled study of intravenous FDY-5301 in patients with anterior ST-segment elevation myocardial infarction. IOCYTE AMI-3
Funder: Faraday Pharmaceuticals, Inc.
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 17/01/2022 - 31/08/2024
IP: JOAQUIN SANCHEZ GILA
Phase 2, double-blind, randomized, placebo-controlled, 4-arm study to study symptoms, function, health-related quality of life, and safety of repeated subcutaneous administration of Ponsegromab compared to placebo in adult participants with heart failure
Funder: PFIZER, SLU
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 02/12/2022 - 30/10/2024
IP: SILVIA LOPEZ FERNANDEZ
Phase II, multicenter, randomized, parallel, three-arm, placebo-controlled study to evaluate the efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction (=45%) after myocardial infarction (HF- REVERT)
Funder: CARDIOR PHARMACEUTICALS GMBH
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 04/04/2022 - 30/09/2024
PI: JESUS GABRIEL SANCHEZ RAMOS
Clinical investigation of ODOCOR II CCM™ electrodes in patients implanted with an OPTIMIZER system.
Funder: IMPULSE DYNAMICS GERMANY GMBH
Type of test: INV. CLINICA PRODUCT SANITARIO COM.
Execution time: 18/06/2021 - 30/12/2022
IP: MIGUEL ALVAREZ LOPEZ
Observational, prospective, 12-month cohort study to analyze changes in the cardiometabolic profile of switching to lurasidone in patients with schizophrenia. RESPECT study
Financer: ANGELINI PHARMA ESPAÑA, SLU
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 16/03/2021 - 30/03/2022
IP: MANUEL LOPEZ PEREZ
Observational study to evaluate the clinical course of high-risk patients undergoing percutaneous coronary intervention (PCI) with implantation of everolimus-eluting stents, using intracoronary techniques to guide and optimize PCI
Funder: CASA DEL CORAZON FOUNDATION
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 08/10/2021 - 30/10/2023
IP: JUAN CABALLERO BORREGO
Conduction system pacing and ablation of the atrioventricular node in patients with heart failure, left ventricular ejection fraction >40%, and permanent atrial fibrillation
Financer: RODRIGUEZ
Type of test: INV. INDEP SANITARY PRODUCT CLINIC.
Execution time: 16/12/2021 - 30/01/2027
PI: MANUEL MOLINA LERMA
Parallel randomized study to assess the utility of routine angiographic review 6 months after percutaneous intervention in the left main trunk (ANGELINE Study)
Funder: EPIC FOUNDATION
Type of test: INV. INDEP SANITARY PRODUCT CLINIC.
Execution time: 17/03/2021 - 30/04/2024
IP: JOAQUIN SANCHEZ GILA
Behavior of edoxaban in patients with nonvalvular atrial fibrillation and heart failure in Spain. EMAYI studio.
Funder: SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 22/01/2021 - 30/08/2022
PI: JESUS GABRIEL SANCHEZ RAMOS
Behavior of edoxaban in patients with nonvalvular atrial fibrillation and heart failure in Spain. EMAYI study
Funder: SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 22/01/2021 - 30/08/2022
IP: FRANCISCO JOSE BERMUDEZ JIMENEZ
Base of the Product Surveillance Record (PSR) platform
Funder: MEDTRONIC BAKKEN RESEARCH CENTER BV
Type of test: INV. CLINICA PRODUCT SANITARIO COM.
Execution time: 06/09/2021 - 30/06/2031
IP: PABLO SANCHEZ MILLAN
Substrate ablation as concomitant treatment in left atrial macroreentrant atrial tachycardia.
Financer: RODRIGUEZ
Type of test: INV. INDEP SANITARY PRODUCT CLINIC.
Execution time: 29/06/2021 - 15/03/2025
IP: MIGUEL ALVAREZ LOPEZ
Dapagliflozin after percutaneous aortic valve prosthesis implantation.
Funder: SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 22/10/2021 - 31/12/2023
IP: JUAN CABALLERO BORREGO
Randomized clinical trial to evaluate the effect of beta-blockers and antiplatelet agents in patients with spontaneous coronary artery dissection.
Funder: SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 03/09/2021 - 31/12/2024
PI: EDUARDO MOLINA NAVARRO
X-TRA (Cross therapy for Re-Do Ablation) Strategy of crossing ablation techniques (cryoballoon and radiofrequency) after recurrence of atrial fibrillation and the need for a new procedure.
Financer: TOQUERO
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 07/07/2021 - 30/09/2024
IP: MIGUEL ALVAREZ LOPEZ
Multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of etripamil nasal spray for the resolution of spontaneous episodes of paroxysmal supraventricular tachycardia. RAPID Study (NODE-301 Part 2)
Funder: MILESTONE PHARMACEUTICALS, INC.
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 15/04/2021 - 31/12/2021
IP: LUIS TERCEDOR SANCHEZ
Prospective Observational Registry of Patients with Heart Failure. ICC-SEC Registry
Funder: SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 19/11/2020 - 19/11/2025
PI: JESUS GABRIEL SANCHEZ RAMOS
BPH registry: HIS BUNDLE PACING (His bundle stimulation registry)
Funder: ABBOTT / SJM COORDINATION CENTER BVBA
Type of test: INV. CLINICA PRODUCT SANITARIO COM.
Execution time: 11/05/2020 - 30/12/2020
PI: MANUEL MOLINA LERMA
Safety and performance of Invicta ventricular DF4 probes with active fixation. APOLLO STUDIO
Funder: SORIN CRM SAS
Type of test: INV. CLINICA PRODUCT SANITARIO COM.
Execution time: 04/08/2020 - 30/10/2024
IP: MIGUEL ALVAREZ LOPEZ
Observational study of inappropriate therapies after ICD replacement
Funder: SORIN CRM SAS
Type of test: INV. CLINICA PRODUCT SANITARIO COM.
Execution time: 17/04/2020 - 30/01/2024
PI: MANUEL MOLINA LERMA
High power radiofrequency applications for faster and safer pulmonary vein ablation - POWER FAST II clinical trial.
Funder: FIBHULP, FOUNDATION FOR BIOMEDICAL RESEARCH OF THE LA PAZ UNIVERSITY HOSPITAL
Type of test: INV. INDEP SANITARY PRODUCT CLINIC.
Execution time: 14/07/2020 - 21/03/2021
PI: ROSA MACIAS RUIZ
Phase II, multicenter, randomized, placebo-controlled, double-blind, parallel-group, search for failure to evaluate the efficacy and safety of BAY 2433334 in patients who have suffered an acute myocardial infarction
Funder: BAYER AG
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 14/02/2020 - 30/10/2021
Multi-Center, Multi-National, Open Label, Safety study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia Open, multicenter and multinational study on the safety of etripamil nasal spray for patients with
Funder: MILESTONE PHARMACEUTICALS, INC.
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 05/03/2020 - 31/08/2021
IP: LUIS TERCEDOR SANCHEZ
Dapagliflozin after implantation of a percutaneous aortic valve prosthesis
Funder: SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 14/12/2020 - 31/12/2023
PI: EDUARDO MOLINA NAVARRO
Double-blind, randomized, placebo-controlled, parallel-group study of AP30663 administered intravenously for cardioversion in patients with atrial fibrillation
Funder: SYNEOS HEALTH IVH UK LIMITED (FORMERLY INVENTIV HEALTH CLINICAL UK LTD),
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 24/06/2019 - 30/12/2020
IP: LUIS TERCEDOR SANCHEZ
